Design, synthesis and biological evaluation of novel chalcone-like compounds as potent and reversible pancreatic lipase inhibitors. (1st January 2021)

• Record Type: Journal Article
• Authors: Huo, Peng-Chao; Hu, Qing; Shu, Sheng; Zhou, Qi-Hang; He, Rong-Jing; Hou, Jie; Guan, Xiao-Qing; Tu, Dong-Zhu; Hou, Xu-Dong; Liu, Peng; Zhang, Nan; Liu, Zhi-Guo; Ge, Guang-Bo
• Is Part Of: Bioorganic & medicinal chemistry. Volume 29(2021)
• Publication Date: 2021-01-01
• Subjects: Pancreatic lipase (PL) -- Chalcone-like compounds -- Inhibition -- Anti-obesity agent; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; Biochemistry -- Periodicals; Chemistry, Clinical -- Periodicals; Chemistry, Organic -- Periodicals; Chimie bio-organique -- Périodiques; Chimie pharmaceutique -- Périodiques; 615.19
• DOI: 10.1016/j.bmc.2020.115853
• Languages: English
• ISSNs: 0968-0896

Abstract

Graphical abstract: Highlights: Series of chalcone-like compounds are designed and synthesized as inhibitors of pancreatic lipase (PL). Structure-activity relationships of chalcone-like compounds as PL inhibitors are summarized. B13 potently inhibits PL in a reversible and mixed inhibition manner. B13 displays potent PL inhibition activity and good stability in gastrointestinal fluids and human liver preparations. Abstract: Pancreatic lipase (PL), a crucial enzyme responsible for hydrolysis of dietary lipids, has been validated as a key therapeutic target to prevent and treat obesity-associated metabolic disorders. Herein, we report the design, synthesis and biological evaluation of a series of chalcone-like compounds as potent and reversible PL inhibitors. Following two rounds of structural modifications at both A and B rings of a chalcone-like skeleton, structure-PL inhibition relationships of the chalcone-like compounds were studied, while the key substituents that would be beneficial for PL inhibition were revealed. Among all tested chalcone-like compounds, compound B13 (a novel chalcone-like compound bearing two long carbon chains) displayed the most potent PL inhibition activity, with an IC50 value of 0.33 μM. Inhibition kinetic analyses demonstrated that B13 could potently inhibit PL-mediated 4-MUO hydrolysis in a mixed inhibition manner, with the Ki value of 0.12 μM. Molecular docking simulations suggested that B13 could tightly bind on PL at both the catalytic site and a non-catalytic site that was located on the surface of PL, which was consistent with the mixed inhibition mode of this agent. In addition, B13 displayed excellent stability in artificial gastrointestinal fluids and good metabolic stability in human liver preparations. Collectively, our findings suggested that chalcone-like compounds were good choices for design and development of orally administrated PL inhibitors, while B13 could be served as a promising lead compound to develop novel anti-obesity agents via targeting on PL.